The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: A systematic review and meta-analysis

Carcinogenesis

Volumn 32, Issue 3, 2011, Pages 411-416

  Wang, Jun ^a   Wang, Baocheng ^a   Chen, Xi ^b   Bi, Jingwang ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b Beijing Huangsi Aesthetical Surgery Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ALLELE; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; EMBASE; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL HISTORY; MEDLINE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SMOKING; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

EID: 79952306961     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq266     Document Type: Article

References (43)

1. Parkin, D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. Chansky, K. et al. (2009) The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J. Thorac. Oncol., 4, 792-801.
3. Vogelstein, B. et al. (1993) The multistep nature of cancer. Trends Genet., 9, 138-141.
4. Steels, E. et al. (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. J., 18, 705-719.
5. Meert, A.P. et al. (2002) The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur. Respir. J., 20, 975-981.
6. Mascaux, C. et al. (2006) Has Cox-2 a prognostic role in non-small cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br. J. Cancer, 95, 139-145.
7. Agathanggelou, A. et al. (2003) Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res., 63, 5344-5351.
8. Allen, N.P. et al. (2007) RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene, 26, 6203-6211.
9. Hesson, L.B. et al. (2007) The role of RASSF1A methylation in cancer. Dis. Markers, 23, 73-87.
10. Dammann, R. et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 25, 315-319.
11. Tommasi, S. et al. (2005) Tumor susceptibility of Rassf1a knockout mice. Cancer Res., 65, 92-98.
12. Burbee, D.G. et al. (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl Cancer Inst., 93, 691-699.
13. Agathanggelou, A. et al. (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509-1518.
14. Zhang, H. et al. (2010) Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 13, 311-316.
15. Tomizawa, Y. et al. (2002) Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin. Cancer Res., 8, 2362-2368.
16. Wang, J. et al. (2004) Value of p16INK4a and RASSF1A promoter hyper-methylation in prognosis of patients with resectable non-small cell lung cancer. Clin. Cancer Res., 10, 6119-6125.
17. Choi, N. et al. (2005) RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. Int. J. Cancer, 115, 575-581.
18. Kim, D.H. et al. (2003) Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res., 63, 3743-3746.
19. Yanagawa, N. et al. (2007) Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer, 58, 131-138.
20. Seng, T.J. et al. (2008) DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br. J. Cancer, 99, 375-382.
21. Saito, K. et al. (2010) Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin. Cancer Res., 16, 2418-2426.
22. Buckingham, L. et al. (2010) PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int. J. Cancer, 126, 1630-1639.
23. Brock, M.V. et al. (2008) DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med., 358, 1118-1128.
24. Niklinska, W. et al. (2009) Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem. Cytobiol., 47, 275-280.
25. Safar, A.M. et al. (2005) Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin. Cancer Res., 11, 4400-4405.
26. Divine, K.K. et al. (2005) Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int. J. Cancer, 114, 400-405.
27. Toyooka, S. et al. (2004) The relationship between aberrant methylation and survival in non-small cell lung cancers. Br. J. Cancer, 91, 771-774.
28. Endoh, H. et al. (2003) RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int. J. Cancer, 106, 45-51.
29. Ramirez, J.L. et al. (2003) Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small cell lung cancer patients. Cancer Lett., 193, 207-216.
30. Gu, J. et al. (2006) Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin. Cancer Res., 12, 7329-7338.
31. Maruyama, R. et al. (2004) Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer, 100, 1472-1477.
32. Parmar, M.K. et al. (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med., 17, 2815-2834.
33. Yusuf, S. et al. (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog. Cardiovasc. Dis., 27, 335-371.
34. Egger, M. et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-634.
35. Kim, D.H. et al. (2003) Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res., 63, 6206-6211.
36. Kim, Y.T. et al. (2005) Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J. Thorac. Cardiovasc. Surg., 130, 1378.
37. Katayama, H. et al. (2007) Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer. Asian Pac. J. Cancer Prev., 8, 221-224.
38. Fischer, J.R. et al. (2007) Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer, 56, 115-123.
39. Olewniczak, S. et al. (2002) Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol. J. Pathol., 53, 183-188.
40. Brundage, M.D. et al. (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest, 122, 1037-1057.
41. Kim, D.H. et al. (2001) p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res., 61, 3419-3424.
42. Zochbauer-Muller, S. et al. (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res., 61, 249-255.
43. Kim, J.S. et al. (2006) Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res., 66, 4049-4054.